RNTX
Rein Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
RNTX Profile
Rein Therapeutics, Inc.
A clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan lung diseases and fibrotic diseases
12407 N. Mopac Expy., Suite 250, #390, Austin, Texas 78758
--
Rein Therapeutics, Inc., was incorporated on August 6, 2001 under the laws of the State of Delaware and began its main business in 2006. The company is a clinical-stage biopharmaceutical company focused on the development and commercialization of a new class of therapeutic agents called binding peptides. The company's lead product candidate, ALRN-6924, targets the tumor suppressor gene p53 to treat a variety of cancers. ALRN-6924, which is currently being tested in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting two primary p53 inhibitory proteins, MDMX and MDM 2. The Company's ongoing ALRN-6924 clinical trials include a Phase 1 trial for the treatment of advanced solid tumors or lymphomas, a Phase 2 trial for the treatment of peripheral T-cell lymphoma, or a Phase 1 trial of PTCL for the treatment of acute myeloid leukemia or AML and advanced myelodysplastic syndrome or MDS, as monotherapy and a Phase 1 trial for the treatment of AML/MDS in combination with cytosine arabinoside or Ara-C.